Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin pens

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

EMA: no new safety concerns with GLP-1 diabetes drugs

CHMP takes issue with study that linked the treatments to serious side effects

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

- PMLiVE

Making mobile health technology work

Augmenting organic life with artificial technology is gaining ground in healthcare

- PMLiVE

Infographic: Pharma investment in Indonesia

Pharma deals in the region since the introduction of Decree 1010 to force companies to manufacture products locally

- PMLiVE

Pharma investment in Indonesia

Healthcare reforms open up huge potential in the market to companies with a carefully tailored expansion strategy

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

- PMLiVE

Medicare puts brake on Lilly’s Alzheimer’s test

Will only reimburse new Alzheimer's diagnostic Amyvid for patients in trials

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

ADA: Lilly’s once-weekly diabetes drug bests Januvia and Byetta

Late-stage trials of dulaglutide show superiority over established brands

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links